Research programme: neurological disorder therapies - Ipsen

Drug Profile

Research programme: neurological disorder therapies - Ipsen

Alternative Names: recombinant botulinum toxins - Ipsen

Latest Information Update: 15 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ipsen
  • Developer Harvard University; Ipsen
  • Class Bacterial proteins; Bacterial toxins; Botulinum toxins; Recombinant proteins
  • Mechanism of Action Acetylcholine inhibitors; Glutamate-antagonists; Neuromuscular blocking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Neuroendocrine tumours; Neurological disorders; Neuromuscular disorders

Most Recent Events

  • 14 Oct 2016 Preclinical trials in Neuromuscular disorders, Neurological disorders and Neuroendocrine tumours in France (unspecified route) (Ipsen pipeline, October 2016)
  • 01 Apr 2015 Ipsen and Harvard University expand their collaboration for the development of therapeutics for Neuroendocrine tumours and Neuromuscular disorders
  • 01 Apr 2015 Early research in Neuroendocrine tumours and Neuromuscular disorders in France (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top